SRNE : Summary for Sorrento Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.95-0.15 (-7.14%)
At close: 4:00PM EDT
People also watch
NKRGLSLBIOTGTXBLCM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.10
Open2.00
Bid1.95 x 6000
Ask2.10 x 1100
Day's Range1.95 - 2.10
52 Week Range1.55 - 8.35
Volume2,601,381
Avg. Volume692,238
Market Cap99.23M
Beta1.88
PE Ratio (TTM)-1.61
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group3 days ago

    Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics

    Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics

  • PR Newswire3 days ago

    Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics

    SAN DIEGO, April 28, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today the closing of a transaction whereby its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), has acquired Virttu Biologics Limited ("Virttu"). As announced by Sorrento on November 16, 2016, TNK and Virttu entered into a binding term sheet setting forth the terms and conditions by which TNK would purchase all of the issued and outstanding equity of Virttu. In consideration for the acquisition, Virttu equity holders received an aggregate of 797,081 shares of common stock of Sorrento based on a $5.55 price per share and reimbursement of certain legal fees and will be eligible to receive an additional approximately $20 million in stock of TNK shares should TNK close a third party equity financing of at least $50 million in proceeds within 12 months of the closing of this transaction.

  • PR Newswire3 days ago

    Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics

    SAN DIEGO, April 28, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today the closing of a transaction whereby its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), has acquired Virttu Biologics Limited ("Virttu"). As announced by Sorrento on November 16, 2016, TNK and Virttu entered into a binding term sheet setting forth the terms and conditions by which TNK would purchase all of the issued and outstanding equity of Virttu. In consideration for the acquisition, Virttu equity holders received an aggregate of 797,081 shares of common stock of Sorrento based on a $5.55 price per share and reimbursement of certain legal fees and will be eligible to receive an additional approximately $20 million in stock of TNK shares should TNK close a third party equity financing of at least $50 million in proceeds within 12 months of the closing of this transaction.